Arm (NASDAQ:ARM) reported what executives described as a record third quarter for fiscal 2026, citing broad-based strength in ...
JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results